Pembrolizumab (Keytruda, MSD) has a marketing authorisation in the UK 'in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD‑L1 with a CPS equal to or greater than 10'.
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
The list price is £2,630 for a 100‑mg vial (excluding VAT; BNF online accessed July 2021).
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.